| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FXYD3 |
| Uniprot No | Q14802 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-38aa |
| 氨基酸序列 | NDLEDKNSPFYYDWHSLQ |
| 预测分子量 | 20.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于FXYD3重组蛋白的关键文献摘要信息：
1. **文献名称**：FXYD3 (Mat-8), a new regulator of Na,K-ATPase
**作者**：Sweadner KJ, et al.
**摘要**：首次发现FXYD3作为钠钾ATP酶(Na,K-ATPase)的调控亚基，重组蛋白实验表明其通过调节钠泵活性影响细胞膜离子转运，可能与肿瘤细胞增殖相关。
2. **文献名称**：Overexpression of FXYD3 protein in human breast cancer
**作者**：Saito T, et al.
**摘要**：通过重组蛋白表达技术证明FXYD3在乳腺癌组织中高表达，并通过激活MAPK信号通路促进肿瘤细胞迁移和侵袭，提示其作为潜在治疗靶点。
3. **文献名称**：Structural insights into FXYD3 modulation of Na+/K+-ATPase
**作者**：Garty H, et al.
**摘要**：利用重组FXYD3蛋白的晶体结构分析，揭示其与钠泵α亚基的相互作用界面，阐明了FXYD3通过构象变化调节钠泵活性的分子机制。
4. **文献名称**：Recombinant FXYD3 alters cellular pH homeostasis in colon cancer cells
**作者**：Li Z, et al.
**摘要**：研究重组FXYD3对结肠癌细胞酸平衡的影响，发现其通过增强钠泵活性维持胞内碱性环境，促进肿瘤耐药性形成。
FXYD3. a member of the FXYD protein family, is a small transmembrane protein encoded by the *FXYD3* gene in humans. This family, characterized by a conserved F-X-Y-D motif, regulates ion transport by modulating the activity of Na+/K+-ATPase, a critical enzyme maintaining cellular electrochemical gradients. FXYD3. also known as mammary tumor-associated protein 8 (MAT-8), is distinct in its tissue-specific expression and oncogenic associations. Structurally, it contains a single transmembrane domain with extracellular N- and intracellular C-termini, spanning ~7-8 kDa. Its interaction with Na+/K+-ATPase fine-tunes ion transport efficiency, influencing cellular processes like pH regulation, volume control, and signal transduction.
FXYD3 gained attention due to its overexpression in multiple cancers, including breast, gastric, and colorectal carcinomas. Studies suggest it promotes tumor progression by enhancing cell proliferation, migration, and survival, possibly through dysregulated ion homeostasis or signaling crosstalk with pathways like EGFR and HER2. Its role in cancer has spurred interest in its potential as a diagnostic marker or therapeutic target.
Recombinant FXYD3 protein is typically produced using bacterial or mammalian expression systems. The recombinant form retains structural and functional properties, enabling in vitro studies to dissect its interaction with Na+/K+-ATPase, oncogenic mechanisms, and screening for inhibitory compounds. Challenges in production include ensuring proper membrane protein folding and post-translational modifications, which may require optimized expression vectors or host cells. Research on recombinant FXYD3 continues to unravel its pathophysiological roles, bridging gaps between ion transport biology and cancer therapeutics.
×
